Abstract：Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome, with the characteristics of early onset of cancer and high cancer incidence. TP53 is widely accepted as a pathogenic gene of LFS. A 2 years and 6 months old boy is reported in this article, who was diagnosed with embryonal rhabdomyosarcoma (RMS) in the left submandibular region. His brother died of RMS, and his grandmother was diagnosed with breast cancer. TP53 gene mutation detection was performed in this patient and some family members, indicating a missense mutation in exon 8 of the patient:c.844C > T (p.Arg282Trp, heterozygous). TP53 mutation was also found in his mother and sister. The boy met the diagnostic criteria for LFS. Among pediatric patients, the most common LFS diseases include osteosarcoma, adrenocortical cancer, central nervous system tumor, and soft tissue tumor. Additionally, leukemia and lymphoma are also involved. LFS patients have a high risk to suffer secondary or even multiple cancers. Therefore, it is necessary to perform genetic detection for pediatric cancer patients, especially those with hereditary predisposition cancers. TP53 mutation often indicates poor prognosis, so it is important to take active treatment and systematic monitoring for LFS family.
XIE Yao,ZHAO Wei-Hong,HUA Ying et al. A rhabdomyosarcoma patient from a Li-Fraumeni syndrome family:a case report and literature review[J]. CJCP, 2017, 19(12): 1263-1266.
Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome[J]. Ann Intern Med, 1969, 71(4):747-752.
[2]
Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome:mutation detection rate and relative frequency of cancers in different familial phenotypes[J]. J Med Genet, 2010, 47(6):421-428.
[3]
Evans DG, Birch JM, Narod SA. Is CHEK2 a cause of the Li-Fraumeni syndrome?[J]. J Med Genet, 2008, 45(1):63-64.
[4]
Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma[J]. Cancer, 2013, 119(2):332-338.
Hu H, Liu J, Liao X, et al. Genetic and functional analysis of a Li Fraumeni syndrome family in China[J]. Sci Rep, 2016, 6:20221.
[7]
Garber JE, Goldstein AM, Kantor AF, et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome[J]. Cancer Res, 1991, 51(22):6094-6097.
[8]
Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds[J]. Cancer Res, 1988, 48(18):5358-5362.
[9]
Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li-Fraumeni syndrome[J]. J Clin Oncol, 2009, 27(26):e108-109.
[10]
Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers[J]. J Clin Oncol, 2015, 33(21):2345-2352.
[11]
Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 2011, 29(23):3185-3193.
[12]
Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes:correlation between tumor type, family structure, and TP53 genotype[J]. Cancer Res, 2003, 63(20):6643-6650.
[13]
Wasserman JD, Novokmet A, Eichler-Jonsson C, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma:a children's oncology group study[J]. J Clin Oncol, 2015, 33(6):602-609.
[14]
Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome[J]. J Natl Cancer Inst, 1998, 90(8):606-611.
[15]
Izawa N, Matsumoto S, Manabe J, et al. A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene[J]. Int J Clin Oncol, 2008, 13(1):78-82.
[16]
Kratz CP, Achatz MI, Brugières L, et al. Cancer Screening Recommendations for individuals with Li-Fraumeni syndrome[J]. Clin Cancer Res, 2017, 23(11):e38-e45.
[17]
Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome:11 year follow-up of a prospective observational study[J]. Lancet Oncol, 2016, 17(9):1295-1305.
[18]
Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome:a prospective observational study[J]. Lancet Oncol, 2011, 12(6):559-567.
[19]
Alderfer MA, Lindell RB, Viadro CI, et al. Should Genetic Testing be Offered for Children? The perspectives of adolescents and emerging adults in families with Li-Fraumeni Syndrome[J]. J Genet Couns, 2017, 26(5):1106-1115.
[20]
Ballinger ML, Mitchell G, Thomas DM. Surveillance recommendations for patients with germline TP53 mutations[J]. Curr Opin Oncol, 2015, 27(4):332-337.
[21]
Daly MB, Pilarski R, Berry M, et al. NCCN Guidelines Insights:Genetic/Familial High-Risk Assessment:Breast and Ovarian, Version 2.2017[J]. J Natl Compr Canc Netw, 2017, 15(1):9-20.
[22]
McBride KA, Ballinger ML, Killick E, et al. Li-Fraumeni syndrome:cancer risk assessment and clinical management[J]. Nat Rev Clin Oncol, 2014, 11(5):260-271.
